Literature DB >> 16957335

Design of miniproteins by the transfer of active sites onto small-size scaffolds.

François Stricher1, Loïc Martin, Claudio Vita.   

Abstract

Natural miniproteins (e.g., animal toxins, protease inhibitors, defensins) can express specific and powerful biological activities by using a stable and minimal (<80 amino acids) structural motif. Artificial activities have been designed on these miniscaffolds by transferring previously identified protein active sites into regions structurally compatible with the site and permissive for sequence mutations. These newly designed miniproteins, presenting a specific and high activity within a small size and well-defined three-dimensional structure, represent novel tools in biology, biotechnology, and medical sciences, and are also useful intermediates to develop new therapeutic agents. The different steps used to design and characterize new bioactive miniproteins are here described in detail. Two successful examples are here reported. The first one is a metal-binding miniprotein (MBP, 37 residues), which possesses a metal specificity resembling that of natural carbonic anhydrase; the second is a CD4 mimic (CD4M33, 27 residues), which is a powerful inhibitor of HIV-1 entry but also a fully functional substitute of the human receptor CD4 and, hence, a potential component of an AIDS vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957335     DOI: 10.1385/1-59745-116-9:113

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Overlapping genes produce proteins with unusual sequence properties and offer insight into de novo protein creation.

Authors:  Corinne Rancurel; Mahvash Khosravi; A Keith Dunker; Pedro R Romero; David Karlin
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

2.  Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.

Authors:  Adi Moseri; Subramanyam Tantry; Fa-Xiang Ding; Fred Naider; Jacob Anglister
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-26       Impact factor: 2.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.